BridgeBio Oncology Therapeutics, In (BBOT) PT Lowered to $25 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BBOT Hot Sheet
Price: $2.30 -0.86%
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 1
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 1
Join SI Premium – FREE
JPMorgan analyst Priyanka Grover lowered the price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) to $25.00 (from $27.00) while maintaining a Overweight rating.
You May Also Be Interested In
- UBS Downgrades PagSeguro (PAGS) to Neutral
- ICICI Securities Upgrades Lloyds Metals & Energy Ltd (LLOYDSME:IN) to Add (2)
- SmartRent (SMRT) PT Raised to $2.25 at B.Riley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
